Overview

An Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-07-20

Target enrollment:

Participant gender:

Summary

The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of PTC518 in participants with HD.

Phase:

PHASE2

Details

Lead Sponsor:

PTC Therapeutics